Capital Research Global Investors
KITE

Capital Research Global Investors’s Kite Pharma, Inc. KITE Stock Holding History

Capital Research Global Investors’s Portfolio KITE Stock Details KITE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-6,936,691
Closed -$719M – 456
2017
Q2 		$719M Buy
6,936,691
+132,400
+2% +$10.8M 0.23% 113
2017
Q1 		$534M Buy
6,804,291
+694,520
+11% +$42.9M 0.17% 136
2016
Q4 		$274M Buy
6,109,771
+34,148
+0.6% +$1.68M 0.09% 201
2016
Q3 		$339M Buy
6,075,623
+61,170
+1% +$3.41M 0.11% 175
2016
Q2 		$301M Buy
6,014,453
+31,700
+0.5% +$1.56M 0.1% 173
2016
Q1 		$275M Buy
5,982,753
+43,200
+0.7% +$2.09M 0.09% 191
2015
Q4 		$366M Buy
5,939,553
+582,093
+11% +$41M 0.13% 162
2015
Q3 		$298M Sell
5,357,460
-127,225
-2% -$8M 0.11% 187
2015
Q2 		$334M Buy
5,484,685
+359,800
+7% +$20.5M 0.11% 190
2015
Q1 		$296M Buy
5,124,885
+1,267,738
+33% +$85M 0.1% 201
2014
Q4 		$222M Buy
3,857,147
+1,467,962
+61% +$61.8M 0.08% 232
2014
Q3 		$65.5M Buy
+2,389,185
New +$59.1M 0.02% 322

Other funds holding KITE

CI
Cowen Inc New York $1.39B AUM 60.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
WCM
Wildcat Capital Management New York $229M AUM 132.65% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
TCSAM
Tyrus Capital S.A.M. Monaco $10.5M AUM 4.88% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Capital Research Global Investors's KITE Position: Q3 2017 in Review

Capital Research Global Investors sold out of Kite Pharma, Inc. (KITE) in Q3 2017, closing a stake of 6,936,691 shares — an estimated $719M sold.

Capital Research Global Investors first reported a position in KITE in Q3 2014 and held it in 12 quarters. The position peaked at $719M in Q2 2017. 244 funds tracked by Wall St. Rank hold KITE as of Q3 2017.

  • Capital Research Global Investors reported no remaining Kite Pharma, Inc. position as of Q3 2017 after selling out during the quarter.
  • Capital Research Global Investors sold 6,936,691 Kite Pharma, Inc. shares in Q3 2017, an estimated $719M.
  • Capital Research Global Investors first reported a position in Kite Pharma, Inc. in Q3 2014 and held it in 12 quarters.
  • Capital Research Global Investors's Kite Pharma, Inc. position peaked at $719M in Q2 2017.
  • 244 funds tracked by Wall St. Rank held Kite Pharma, Inc. as of Q3 2017.

Based on Capital Research Global Investors's 13F filing for Q3 2017, filed 14 Nov 2017.